BR9911648A - Composição farmacêutica de liberação controlada e processo de liberação de agente farmaceuticamente ativo - Google Patents

Composição farmacêutica de liberação controlada e processo de liberação de agente farmaceuticamente ativo

Info

Publication number
BR9911648A
BR9911648A BR9911648-0A BR9911648A BR9911648A BR 9911648 A BR9911648 A BR 9911648A BR 9911648 A BR9911648 A BR 9911648A BR 9911648 A BR9911648 A BR 9911648A
Authority
BR
Brazil
Prior art keywords
active agent
pharmaceutically active
molecular weight
average molecular
controlled release
Prior art date
Application number
BR9911648-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Rajen Shah
Arun P Patel
Roy T Sandry
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22627919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9911648(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR9911648A publication Critical patent/BR9911648A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9911648-0A 1998-10-14 1999-10-12 Composição farmacêutica de liberação controlada e processo de liberação de agente farmaceuticamente ativo BR9911648A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17249198A 1998-10-14 1998-10-14
PCT/EP1999/007627 WO2000021525A2 (en) 1998-10-14 1999-10-12 Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent

Publications (1)

Publication Number Publication Date
BR9911648A true BR9911648A (pt) 2001-03-20

Family

ID=22627919

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911648-0A BR9911648A (pt) 1998-10-14 1999-10-12 Composição farmacêutica de liberação controlada e processo de liberação de agente farmaceuticamente ativo

Country Status (30)

Country Link
EP (1) EP1121116B1 (https=)
JP (2) JP2002527388A (https=)
KR (1) KR100517090B1 (https=)
CN (1) CN1196481C (https=)
AR (2) AR020780A1 (https=)
AT (1) ATE382345T1 (https=)
AU (1) AU765475B2 (https=)
BR (1) BR9911648A (https=)
CA (1) CA2346868C (https=)
CO (1) CO5140079A1 (https=)
CY (1) CY1107874T1 (https=)
DE (1) DE69937891T2 (https=)
DK (1) DK1121116T3 (https=)
ES (1) ES2297936T3 (https=)
HK (1) HK1040920B (https=)
HU (1) HUP0104268A3 (https=)
ID (1) ID29350A (https=)
IL (2) IL142375A0 (https=)
MY (1) MY121105A (https=)
NO (1) NO327285B1 (https=)
NZ (1) NZ511010A (https=)
PE (1) PE20001110A1 (https=)
PL (1) PL198850B1 (https=)
PT (1) PT1121116E (https=)
RU (1) RU2259826C2 (https=)
SK (2) SK286596B6 (https=)
TR (1) TR200101088T2 (https=)
TW (1) TW577738B (https=)
WO (1) WO2000021525A2 (https=)
ZA (1) ZA200103001B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569461B1 (en) 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
CZ20024015A3 (cs) 2000-06-09 2003-04-16 Lek Pharmaceutical D.D. Stabilní farmaceutický produkt a jeho formulace
ATE361060T1 (de) 2000-09-29 2007-05-15 Solvay Pharm Bv Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
AU2003262059A1 (en) * 2002-09-11 2004-04-30 Takeda Pharmaceutical Company Limited Sustained release preparation
CA2520197A1 (en) * 2003-04-23 2004-11-04 Ferring B.V. Sachet for a pharmaceutical composition
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
WO2007016757A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
KR20080094837A (ko) * 2006-02-24 2008-10-24 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 약학 조성물
RU2342144C1 (ru) * 2007-04-05 2008-12-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтический состав, обладающий противосудорожным и психотропным действием
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
AU2014205356A1 (en) * 2013-01-09 2015-07-30 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
CN106344535B (zh) * 2016-08-29 2019-09-20 济南康和医药科技有限公司 一种氟伐他汀钠微孔渗透泵控释片及其制备方法
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
KR102833111B1 (ko) 2018-09-25 2025-07-10 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 칼슘 알파-케토글루타레이트의 제조 방법
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
US20220265586A1 (en) * 2019-06-10 2022-08-25 Ponce De Leon Health Designated Activity Company Sustained-release compositions of alpha-ketoglutarate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
CA2045428A1 (en) * 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
CZ288545B6 (cs) * 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
CO5140079A1 (es) 2002-03-22
DE69937891D1 (de) 2008-02-14
SK5092001A3 (en) 2001-09-11
WO2000021525A2 (en) 2000-04-20
HUP0104268A2 (hu) 2002-04-29
RU2259826C2 (ru) 2005-09-10
AR069281A2 (es) 2010-01-13
JP2002527388A (ja) 2002-08-27
HK1040920A1 (en) 2002-06-28
WO2000021525A3 (en) 2000-08-10
NO20011695D0 (no) 2001-04-04
ZA200103001B (en) 2002-07-11
AR020780A1 (es) 2002-05-29
KR100517090B1 (ko) 2005-09-27
PE20001110A1 (es) 2000-11-01
NO327285B1 (no) 2009-06-02
CA2346868C (en) 2008-09-09
JP4938383B2 (ja) 2012-05-23
IL142375A0 (en) 2002-03-10
EP1121116B1 (en) 2008-01-02
IL142375A (en) 2012-01-31
CY1107874T1 (el) 2013-06-19
EP1121116A2 (en) 2001-08-08
ES2297936T3 (es) 2008-05-01
PL198850B1 (pl) 2008-07-31
KR20010080156A (ko) 2001-08-22
CN1328454A (zh) 2001-12-26
MY121105A (en) 2005-12-30
ATE382345T1 (de) 2008-01-15
DE69937891T2 (de) 2008-12-11
HUP0104268A3 (en) 2002-06-28
NZ511010A (en) 2003-10-31
DK1121116T3 (da) 2008-05-13
TW577738B (en) 2004-03-01
PL348109A1 (en) 2002-05-06
CA2346868A1 (en) 2000-04-20
JP2006298945A (ja) 2006-11-02
AU6090999A (en) 2000-05-01
SK286595B6 (sk) 2009-01-07
HK1040920B (zh) 2005-07-29
SK286596B6 (sk) 2009-01-07
CN1196481C (zh) 2005-04-13
TR200101088T2 (tr) 2001-10-22
AU765475B2 (en) 2003-09-18
ID29350A (id) 2001-08-23
NO20011695L (no) 2001-05-30
PT1121116E (pt) 2008-03-12

Similar Documents

Publication Publication Date Title
BR9911648A (pt) Composição farmacêutica de liberação controlada e processo de liberação de agente farmaceuticamente ativo
TWI544922B (zh) 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
RU2004137118A (ru) Фармацевтическая композиция для контролируемого высвобождения активных веществ и способ ее изготовления
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
BR0007360A (pt) Composição de liberação controlada
BRPI0512177A (pt) formulação de liberação modificada de memantina
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
BR9901782A (pt) Forma para dosagem de nefazodona.
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
WO2004108162A3 (en) Controlled release pharmaceutical composition
KR101066763B1 (ko) 온도 반응성 전달계
BR9916881A (pt) Métodos para tratamento do câncer ovariano, composições de poli(fosfoéster) e artigos biodegradáveis das mesmas
Owen et al. An in vitro study of plasticized poly (lactic‐co‐glycolic acid) films as possible guided tissue regeneration membranes: material properties and drug release kinetics
UY25443A1 (es) Procedimiento para la preparacion de principio activo peroral
JP2002527388A5 (https=)
CU23318A7 (es) Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida
ATE375789T1 (de) Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel
JP2003206241A (ja) 眼科用剤
BR9814751A (pt) Composição sólida seca para liberação de droga, processo para a preparação da mesma, e, uso de um grande número de partìculas porosas inorgânicas que são compostas de hidroxiapatita de cerâmica.
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
NZ518145A (en) Novel hormonal composition and the use thereof
JP2003107416A (ja) コンタクトレンズ用組成物及び洗眼剤組成物
KR20010022113A (ko) 주성분으로서 벤조피란 유도체를 함유하는 수성 액체 제약조성물
ES2306827T3 (es) Composiciones de betahistina de liberacion controlada.
AR002972A1 (es) Pildoras que tienen una matriz farmaceutica que proporcionan un perfil apropiado de liberacion de la droga, composicion para la preparacion de dichamatriz, proceso para preparar dichas pildoras y formas de dosificacion de dicha composicion.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/22, A61K 9/20, A61P 3/06

Ipc: A61K 31/22 (2008.01), A61K 9/20 (2008.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AOS ARTIGOS 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/22 (2006.01), A61K 9/20 (2006.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]